Riskpilot← Back to searchSign inGet full accessSidera Bio ApS
APSActiveCVR 44381699Fruebjergvej 3Research and experimental development on natural sciences and engineering · NACE 7210Est. 20236 employees
Revenue 2024
DKK -6,7M
EBITDA margin
104.5%
Equity ratio
-105.5%
Financial strength
Net profit 2024
DKK -6,6M
6 employees
| Revenue | DKK -6,7M | — |
| EBITDA | DKK -7M | — |
| Net profit | DKK -6,6M | — |
| Total assets | DKK 6,3M | — |
| Equity | DKK -6,6M | — |
| Employees | 6 | — |
Legal name
Sidera Bio ApS
CVR number
44381699
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
19. oktober 2023
Share capital
DKK 567.867
Employees
6 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med et medlem af bestyrelsen, af bestyrelsens
formand i forening med et medlem af direktionen, eller af den samlede
bestyrelse.
Company purpose
Selskabets formål er forskning, udvikling, produktion og salg af lægemidler og andre beslægtede forretningsområder efter bestyrelsens skøn.
Address
Fruebjergvej 3
Phone
+4553881254
Email
Martin.Santini@siderabio.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2024 |
|---|---|
| Revenue | -6.685 |
| Staff expenses | -303 |
| EBITDA | -6.988 |
| Depreciation & amort. | -4 |
| EBIT | -6.992 |
| Net financials | -372 |
| Profit before tax | -7.365 |
| Tax | -737 |
| Net profit | -6.627 |
| Item | 2024 |
|---|---|
| Total assets | 6.277 |
| Equity | -6.622 |
| Long-term debt | 12.351 |
| Short-term debt | 548 |
| Total debt | 12.899 |
EBITDA margin
-698844400.0%
This company
15.8%
Market median
-4423065923% vs market
20242024
Equity ratio
-105.5%
This company
38.2%
Market median
-376% vs market
20242024
Return on equity
-662723700.0%
This company
18.4%
Market median
-3601759339% vs market
20242024
Net profit margin
-662723700.0%
This company
8.1%
Market median
-8181774174% vs market
20242024
Asset turnover
-1.07×
This company
1.12×
Market median
-196% vs market
20242024
Debt / equity
1.95×
This company
0.62×
Market median
-215% vs market
20242024
- Annual report 2024Filed via CVR / Virk · Period 2023-10-19 – 2024-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KF Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
TG Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2025 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 25.0% | 25.0% | 2025 | |
Novo Holdings A/S | Company | 15.0% | 15.0% | 2025 |
| Individual | 15.0% | 15.0% | 2025 | |
| Individual | 10.0% | 10.0% | 2025 | |
| Individual | 5.0% | 5.0% | 2026 | |
| Individual | 5.0% | 5.0% | 2025 | |
BHNS Holding ApS | Company | 20.0% | 20.0% | 2024 |
| Individual | 20.0% | 20.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
Sidera Bio ApS Board members of Sidera Bio ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Keld Flintholm Jørgensen | Chief Executive Officer | 0 companies |
| Thomas Gundelund Rasmussen | Chief Executive Officer | 0 companies |
| Stefan Emanuel Luzi | Board of Directors | 0 companies |
| Peter Høngård Andersen | Chairman | 0 companies |
| Kasper Lage Hansen | Board of Directors | 0 companies |
| Nandita Shangari | Board of Directors | 0 companies |
| Søren Møller | Board of Directors | 0 companies |
| Tim Lohoff | Board of Directors | 0 companies |